Every AI newsletter,Beijing Capital Securities issued a research report on August 17 and stated that it maintains the buy rating of Changchun Hi-tech (000661.SZ, latest price: 303.15 yuan). The reasons for the rating mainly include: 1) The company’s performance continues to grow, and growth hormone continues to increase; 2) Growth hormone continues to expand treatment scenarios, and channels are sinking to help new patients grow rapidly; 3) The vaccine pipeline is rich, and a variety of vaccine products are on the market soon. Risk warning: policy risks such as centralized procurement, single product risk, and R&D failure risk.
AI comment: Changchun Gaoxin has attracted the attention of 14 brokerage research reports in the past month, buying 13 companies, with an average target price of 509.04 yuan, which is 205.89 yuan higher than the latest price of 303.15 yuan, and the target average price has increased by 67.92%.
Every Jing Toutiao (nbdtoutiao)——After 4.025% annuity insurance was suspended, the selling of this type of life insurance was “crazy”. 12 insurance companies launched new products, but behind the popularity, the supply side stopped selling and the sales side arbitrage. Can the increased lifetime life insurance be bought?
(Reporter Wang Xiaobo)
Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. According to this operation, at your own risk.
Copyright Notice
1This article is the original work of “Daily Economic News”.
2
Without the authorization of “Daily Economic News”, it may not be used in any way, including but not limited to reprinting, extracting, copying or creating mirror images, etc., offenders must be investigated.
3Copyright cooperation telephone: 021-60900099.